Douglas V Faller

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 5

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia

Top Venues

Targeted oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Angela Dispenzieri, Efstathios Kastritis, Ashutosh D Wechalekar, Stefan O Schönland, Kihyun Kim, Vaishali Sanchorawala, Heather J Landau, Fiona Kwok, Kenshi Suzuki, Raymond L Comenzo, Deborah Berg, Guohui Liu, Arun Kumar, Douglas V Faller, Giampaolo Merlini
A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia (2021)
Toshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, Kan Yonemori, Tomoko Yanai, Douglas V Faller, Lwona Dobler, Neeraj Gupta, Farhad Sedarati, Kyu-Pyo Kim
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. Targeted oncology (2021)
Fabien Muselli, Lucas Mourgues, Rita Morcos, Nathalie Rochet, Marielle Nebout, Agnès Guerci-Bresler, Douglas V Faller, Robert M William, Rana Mhaidly, Els Verhoeyen, Laurence Legros, Jean-François Peyron, Didier Mary
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models. Cancers 13 (7) (2021)
Mikkael A Sekeres, Justin Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Patricia Font Lopez, Joshua F Zeidner, Maria Diez Campelo, Carlos Graux, Jane Liesveld, Dominik Selleslag, Nikolay Tzvetkov, Robert J Fram, Dan Zhao, Jill Bell, Sharon Friedlander, Douglas V Faller, Lionel Adès
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 35 (7) (2021)
Ronan T Swords, Steven Coutre, Michael B Maris, Joshua F Zeidner, James M Foran, Jose Cruz, Harry P Erba, Jesus G Berdeja, Wayne Tam, Saran Vardhanabhuti, Lwona Dobler, Hélène M Faessel, Ajeeta B Dash, Farhad Sedarati, Douglas V Faller, Michael R Savona
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131 (13) (2018)